Multispecific antibodies:
next generation therapeutics targeting complex disease biology

Home / R&D / Next generation therapeutics / Multispecific antibodies


What are multispecific antibodies?

Multispecific antibodies are novel drug modalities that can bind simultaneously to two or more target proteins or bridge two different cells, to elicit a therapeutic effect to treat cancer and other diseases.

They comprise of monoclonal antibodies (mAb), which are designed to target complex disease biology characterised by multiple drivers, and complement conventional, ‘monospecific’ medicines which recognise a single target. An example of multispecifics is bispecific antibodies.1



Multispecific antibody activating cytotoxic T cells in the innate immune system:

T cell engagers (TCE) are a type of multispecific antibody that are engineered to activate the immune system’s T cells and redirect them to recognise and kill cancer cells.

T cell engagers (TCE) are a type of multispecific antibody that are engineered to activate the immune system’s T cells and redirect them to recognise and kill cancer cells.


Join us

If you believe in the power of what science can do, join us in our endeavour to push the boundaries of science to deliver life-changing medicines.


Collaborate with us

We know that however innovative our science, however effective our medicines and delivery, to achieve all we want to achieve, we cannot do it alone.